GlobeNewswire Inc.Sep 3, 3:50 PM ET▼ Negative
Under investigation for potential breach of fiduciary duties; shareholders will own only 6.8% of combined company, suggesting unfavorable deal terms
Werewolf Therapeutics news
$0.9100−2.15%
Close Sep 29, 2026 · split-adjustedArticles · 30 days1English, de-duplicated
Positive00% of coverage
Neutral00%
Negative1100% of coverage
About Werewolf Therapeutics
GlobeNewswire Inc.Mar 27, 7:00 AM ET▼ Negative
While the company shows improved operational efficiency with reduced expenses and lower net losses, the initiation of a strategic alternatives exploration process typically signals financial distress or inability to execute standalone strategy. The declining cash position ($57.1M from $110.9M year-over-year) and limited runway into Q4 2026 indicate the company is under financial pressure and may be forced into unfavorable transaction terms. The lack of defined timeline and no assurance of value-enhancing outcomes further suggests uncertainty and potential shareholder dilution.
Also mentions HOWL
Articles that tag HOWL but are mainly about other companies.
BenzingaFeb 27, 4:05 PM ET▼ Negative
Hired Piper Sandler to run sale process following announcement of 64% workforce reduction and major restructuring to cut operating costs.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology